Forty and Beyond: A SWOT Analysis of PGT-A in the Context of Aging and Fertility

Document Type : Original Article

Authors

1 Obstetrics and Gynecology Department, Faculty of Medicine, Alexandria University, Egypt.

2 Egyptian Foundation of Reproductive Medicine and Embryology (EFRE), Egypt.

3 Agial Fertility Center, Alexandria, Egypt.

4 Madina Fertility Center, Madina Women's Hospital, Alexandria, Egypt.

5 Obstetrics and Gynecology Department, Faculty of Medicine, Hodeidah University, Al-Hodeidah, Yemen.

6 Obstetrics and Gynecology Department, Faculty of Medicine, Aswan University, Egypt.

7 Dar Alteb Infertility Center, Alexandria, Egypt.

Abstract

Preimplantation genetic testing for aneuploidy (PGT-A) is widely used in in vitro fertilization (IVF) to detect chromosomal abnormalities in embryos. This testing employs various platforms—including quantitative PCR, array comparative genomic hybridization (aCGH), and next-generation sequencing (NGS)—each with its own advantages and limitations. The goal of these technologies is to enhance clinical outcomes, reduce the time to pregnancy, and ultimately improve the likelihood of delivering a healthy baby. Additionally, emerging approaches such as non-invasive PGT using spent culture medium show promise for future application.
However, it is important to recognize that PGT-A functions as a screening tool rather than a definitive indicator of the chromosomal status of embryos or fetuses. While advocates claim that PGT-A enhances IVF outcomes, critics argue that it lacks adequate clinical validation and may reduce live birth rates due to its high false-positive rate.This article employs a SWOT analysis to evaluate the advantages, challenges, opportunities, and risks of PGT-A in women of advanced maternal age.

Keywords

Main Subjects

Journal of Reproductive Medicine and Embryology
Volume 1, Issue 4
February 2025
Pages 262-275

Files

Share

How to cite

Statistics